HGS/GSK's Benlysta stumbles at secondary endpoint of Phase III study
This article was originally published in Scrip
Human Genome Sciences and GlaxoSmithKline's human monoclonal antibody therapy Benlysta (belimumab), for the treatment of systemic lupus erythematosus (SLE), did not significantly increase patient response rates at 76 weeks compared with placebo – a key secondary endpoint of its BLISS-76 Phase III pivotal trial.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.